

CENTER FOR DRUG EVALUATION AND RESEARCH

Approval Package for:

APPLICATION NUMBER:

214429Orig1s000

Trade Name: N/A

Generic or Proper Name: Fexinidazole tablets, 600 mg

Sponsor: Sanofi-Aventis U.S. LLC

Approval Date: July 16, 2021

Indication: For the treatment of both first-stage (hemolymphatic) and second-stage (meningoencephalitic) human African trypanosomiasis (HAT) due to *Trypanosoma brucei gambiense* in patients 6 years of age and older and weighing at least 20 kg.

CENTER FOR DRUG EVALUATION AND RESEARCH

214429Orig1s000

CONTENTS

Reviews / Information Included in this NDA Review.

Approval Letter	X
Other Action Letters	X
Labeling	X
REMS	
Officer/Employee List	X
Multidiscipline Review(s) • Summary Review • Office Director • Cross Discipline Team Leader • Clinical • Non-Clinical • Statistical • Clinical Pharmacology	X
Product Quality Review(s)	X
Clinical Microbiology / Virology Review(s)	
Other Reviews	X
Risk Assessment and Risk Mitigation Review(s)	X
Proprietary Name Review(s)	
Administrative/Correspondence Document(s)	X

**CENTER FOR DRUG EVALUATION AND
RESEARCH**

APPLICATION NUMBER:

214429Orig1s000

APPROVAL LETTER



NDA 214429

NDA APPROVAL

Drugs for Neglected Diseases *initiative*
c/o sanofi-aventis U.S. LLC
A SANOFI COMPANY
Attention: Michael Macalush, MS
Director, U.S. and Global Regulatory Affairs
55 Corporate Drive
Mail Code: 55C-205A
Bridgewater, NJ 08807-5925

Dear Mr. Macalush:

Please refer to your new drug application (NDA) dated March 12, 2020, received March 12, 2020, and your amendments, submitted under section 505(b) of the Federal Food, Drug, and Cosmetic Act (FDCA) for Fexinidazole tablets, 600 mg.

We acknowledge receipt of your amendment dated May 18, 2021, which constituted a complete response to our November 12, 2020, action letter.

This NDA provides for the use of Fexinidazole tablets, 600 mg, for the treatment of both first-stage (hemolympathic) and second-stage (meningoencephalitic) human African trypanosomiasis (HAT) due to *Trypanosoma brucei gambiense* in patients 6 years of age and older and weighing at least 20 kg.

Limitation of Use:

Due to the decreased efficacy observed in patients with severe second stage HAT (cerebrospinal fluid white blood cell count (CSF-WBC) greater than 100 cells/ μ L) due to *T. brucei gambiense* disease, Fexinidazole tablets should only be used in these patients if there are no other available treatment options.

APPROVAL & LABELING

We have completed our review of this application, as amended. It is approved, effective on the date of this letter, for use as recommended in the enclosed agreed-upon labeling.

WAIVER OF ½ PAGE LENGTH REQUIREMENT FOR HIGHLIGHTS

We are waiving the requirements of 21 CFR 201.57(d)(8) regarding the length of Highlights of Prescribing Information. This waiver applies to all future supplements containing revised labeling unless we notify you otherwise.

CONTENT OF LABELING

As soon as possible, but no later than 14 days from the date of this letter, submit the content of labeling [21 CFR 314.50(l)] in structured product labeling (SPL) format using the FDA automated drug registration and listing system (eLIST), as described at FDA.gov.¹ Content of labeling must be identical to the enclosed labeling (text for the Prescribing Information) as well as annual reportable changes not included in the enclosed labeling. Information on submitting SPL files using eLIST may be found in the guidance for industry *SPL Standard for Content of Labeling Technical Qs and As*.²

The SPL will be accessible via publicly available labeling repositories.

CARTON AND CONTAINER LABELING

Submit final printed carton and container labeling that are identical to the enclosed carton and container labeling, as soon as they are available, but no more than 30 days after they are printed. Please submit these labeling electronically according to the guidance for industry *Providing Regulatory Submissions in Electronic Format — Certain Human Pharmaceutical Product Applications and Related Submissions Using the eCTD Specifications*. For administrative purposes, designate this submission “**Final Printed Carton and Container Labeling for approved NDA 214429.**” Approval of this submission by FDA is not required before the labeling is used.

DATING PERIOD

The expiry dating period for Fexinidazole tablets, 600 mg, shall be 48 months from the date of manufacture when stored below 30°C.

TROPICAL DISEASE PRIORITY REVIEW VOUCHER

We also inform you that you have been granted a tropical disease priority review voucher, as provided under section 524 of the FDCA. This voucher entitles you to designate a single human drug application submitted under section 505(b)(1) of the FDCA or a single biologic application submitted under section 351 of the Public Health

¹ <http://www.fda.gov/ForIndustry/DataStandards/StructuredProductLabeling/default.htm>

² We update guidances periodically. For the most recent version of a guidance, check the FDA Guidance Documents Database <https://www.fda.gov/RegulatoryInformation/Guidances/default.htm>.

Service Act as qualifying for a priority review. Such an application would not have to meet any other requirements for a priority review. This priority review voucher may be transferred by you to another sponsor of a human drug or biologic application. When redeeming this priority review voucher, you should refer to this letter as an official record of the voucher. If the voucher is transferred, the sponsor to whom the voucher has been transferred should include a copy of this letter (which will be posted on our Web site as are all approval letters) and proof that the voucher was transferred. In addition, this priority review voucher has been assigned a tracking number, PRV NDA 214429. All correspondences related to this voucher should refer to this tracking number. For additional information regarding the priority review voucher see the guidance for industry *Tropical Disease Priority Review Vouchers*.

MARKET PACKAGE

Please submit one market package of the drug product when it is available to the following address:

Alison Rodgers
Food and Drug Administration
Center for Drug Evaluation and Research
White Oak Building 22, Room: 6247
10903 New Hampshire Avenue
Silver Spring, Maryland
Use zip code **20903** if shipping via United States Postal Service (USPS).
Use zip code **20993** if sending via any carrier other than USPS (e.g., UPS, DHL, FedEx).

ADVISORY COMMITTEE

Your application for fexinidazole was not referred to an FDA advisory committee because outside expertise was not necessary; there were no controversial issues that would benefit from advisory committee discussion.

PROPRIETARY NAME

If you intend to have a proprietary name for this product, the name and its use in the labeling must conform to the specifications under 21 CFR 201.10 and 201.15. We recommend that you submit a request for a proposed proprietary name review. (See the guidance for industry *Contents of a Complete Submission for the Evaluation of Proprietary Names*, and *PDUFA Reauthorization Performance Goals and Procedures Fiscal Years 2018 through 2022*.)

REQUIRED PEDIATRIC ASSESSMENTS

Under the Pediatric Research Equity Act (PREA) (21 U.S.C. 355c), all applications for new active ingredients (which includes new salts and new fixed combinations), new indications, new dosage forms, new dosing regimens, or new routes of administration are required to contain an assessment of the safety and effectiveness of the product for the claimed indication in pediatric patients unless this requirement is waived, deferred, or inapplicable.

Because this drug product for this indication has an orphan drug designation, you are exempt from this requirement.

POSTMARKETING REQUIREMENTS UNDER 505(o)

Section 505(o)(3) of the Federal Food, Drug, and Cosmetic Act (FDCA) authorizes FDA to require holders of approved drug and biological product applications to conduct postmarketing studies and clinical trials for certain purposes, if FDA makes certain findings required by the statute.

We have determined that an analysis of spontaneous postmarketing adverse events reported under subsection 505(k)(1) of the FDCA will not be sufficient to identify an unexpected serious risk of harm to pregnant mothers and newborns exposed to fexinidazole due to the low incidence of Human African Trypanosomiasis caused by *Trypanosoma brucei gambiense* in the United States.

Furthermore, the active postmarket risk identification and analysis system as available under section 505(k)(3) of the FDCA will not be sufficient to assess this serious risk.

Therefore, based on appropriate scientific data, FDA has determined that you are required to conduct the following study:

3952-1 Submit the results of your current worldwide descriptive study that is collecting prospective and retrospective data in women exposed to fexinidazole during pregnancy to assess risk of pregnancy and maternal complications, adverse effects on the developing fetus and neonate, and adverse effects on the infant.

The timetable you submitted on November 10, 2020, states that you will conduct this study according to the following schedule:

Final Protocol Submission:	Submitted
Trial Completion:	04/2023
Final Report Submission:	04/2024

FDA considers the term *final* to mean that the applicant has submitted a protocol, the FDA review team has sent comments to the applicant, and the protocol has been revised as needed to meet the goal of the study or clinical trial.³

Finally, we have determined that only clinical trials (rather than nonclinical or observational studies) will be sufficient to assess a signal of serious risk of Fexinidazole tablets on the PK exposure of CYP3A4 drug substrates and to assess the pharmacokinetics of fexinidazole and the M1 and M2 metabolites in subjects with hepatic impairment, and if dosage adjustment of Fexinidazole tablets is needed in this subpopulation of subjects.

Therefore, based on appropriate scientific data, FDA has determined that you are required to conduct the following trials:

3952-2 Conduct a clinical drug-drug interaction (DDI) trial to evaluate the effect of repeat doses of Fexinidazole tablets on the pharmacokinetics of midazolam, which is a cytochrome P450 (CYP) 3A4 sensitive drug substrate, in healthy subjects.

The timetable you submitted on November 02, 2020, states that you will conduct this trial according to the following schedule:

Draft Protocol Submission:	Submitted
Final Protocol Submission:	09/2021
Trial Completion:	09/2022
Final Report Submission:	06/2023

3952-3 Conduct a clinical pharmacokinetic (PK) trial to evaluate the PK of fexinidazole and the M1 and M2 metabolites in subjects with hepatic impairment who fall in the Child-Pugh (CP) categories of mild (CP-A) and moderate (CP-B) impairment.

The timetable you submitted on November 02, 2020, states that you will conduct this trial according to the following schedule:

Draft Protocol Submission:	09/2021
Final Protocol Submission:	12/2021
Trial Completion:	03/2023
Final Report Submission:	03/2024

³ See the guidance for Industry *Postmarketing Studies and Clinical Trials—Implementation of Section 505(o)(3) of the Federal Food, Drug, and Cosmetic Act* (October 2019).
<https://www.fda.gov/RegulatoryInformation/Guidances/default.htm>.

FDA considers the term *final* to mean that the applicant has submitted a protocol, the FDA review team has sent comments to the applicant, and the protocol has been revised as needed to meet the goal of the study or clinical trial.⁴

Submit clinical protocol(s) to IND 110365 with a cross-reference letter to this NDA. Submit nonclinical and chemistry, manufacturing, and controls protocols and all final report(s) to your NDA. Prominently identify the submission with the following wording in bold capital letters at the top of the first page of the submission, as appropriate:

Required Postmarketing Protocol Under 505(o), Required Postmarketing Final Report Under 505(o), Required Postmarketing Correspondence Under 505(o).

Submission of the protocol(s) for required postmarketing observational studies to your IND is for purposes of administrative tracking only. These studies do not constitute clinical investigations pursuant to 21 CFR 312.3(b) and therefore are not subject to the IND requirements under 21 CFR part 312 or FDA's regulations under 21 CFR parts 50 (Protection of Human Subjects) and 56 (Institutional Review Boards).

Section 505(o)(3)(E)(ii) of the FDCA requires you to report periodically on the status of any study or clinical trial required under this section. This section also requires you to periodically report to FDA on the status of any study or clinical trial otherwise undertaken to investigate a safety issue. Section 506B of the FDCA, as well as 21 CFR 314.81(b)(2)(vii) requires you to report annually on the status of any postmarketing commitments or required studies or clinical trials.

FDA will consider the submission of your annual report under section 506B and 21 CFR 314.81(b)(2)(vii) to satisfy the periodic reporting requirement under section 505(o)(3)(E)(ii) provided that you include the elements listed in 505(o) and 21 CFR 314.81(b)(2)(vii). We remind you that to comply with 505(o), your annual report must also include a report on the status of any study or clinical trial otherwise undertaken to investigate a safety issue. Failure to submit an annual report for studies or clinical trials required under 505(o) on the date required will be considered a violation of FDCA section 505(o)(3)(E)(ii) and could result in enforcement action.

POSTMARKETING COMMITMENTS NOT SUBJECT TO THE REPORTING REQUIREMENTS UNDER SECTION 506B

We remind you of your postmarketing commitment:

3952-4 Develop a procedure for the (b) (4) and establish it as a first GMP step in the manufacturing process for fexinidazole drug substance.

⁴ See the guidance for Industry *Postmarketing Studies and Clinical Trials—Implementation of Section 505(o)(3) of the Federal Food, Drug, and Cosmetic Act* (October 2019).
<https://www.fda.gov/RegulatoryInformation/Guidances/default.htm>.

The timetable you submitted on August 03, 2020, states that you will conduct this study according to the following schedule:

Interim Report Submission:	02/01/2022
Final Report Submission:	08/01/2022

The above change in the manufacturing process of fexinidazole drug substance should be submitted as a prior-approval supplement to the NDA.

Submit clinical protocols to your IND 110365 for this product. Submit nonclinical and chemistry, manufacturing, and controls protocols and all postmarketing final reports to this NDA. In addition, under 21 CFR 314.81(b)(2)(vii) and 314.81(b)(2)(viii) you should include a status summary of each commitment in your annual report to this NDA. The status summary should include expected summary completion and final report submission dates, any changes in plans since the last annual report, and, for clinical studies/trials, number of patients entered into each study/trial. All submissions, including supplements, relating to these postmarketing commitments should be prominently labeled **“Postmarketing Commitment Protocol,” “Postmarketing Commitment Final Report,” or “Postmarketing Commitment Correspondence.”**

PROMOTIONAL MATERIALS

You may request advisory comments on proposed introductory advertising and promotional labeling. For information about submitting promotional materials, see the final guidance for industry *Providing Regulatory Submissions in Electronic and Non-Electronic Format—Promotional Labeling and Advertising Materials for Human Prescription Drugs*.⁵

As required under 21 CFR 314.81(b)(3)(i), you must submit final promotional materials, and the Prescribing Information, at the time of initial dissemination or publication, accompanied by a Form FDA 2253. Form FDA 2253 is available at FDA.gov.⁶ Information and Instructions for completing the form can be found at FDA.gov.⁷

REPORTING REQUIREMENTS

We remind you that you must comply with reporting requirements for an approved NDA (21 CFR 314.80 and 314.81).

⁵ For the most recent version of a guidance, check the FDA guidance web page at

<https://www.fda.gov/media/128163/download>.

⁶ <http://www.fda.gov/downloads/AboutFDA/ReportsManualsForms/Forms/UCM083570.pdf>

⁷ <http://www.fda.gov/downloads/AboutFDA/ReportsManualsForms/Forms/UCM375154.pdf>

POST APPROVAL FEEDBACK MEETING

New molecular entities qualify for a post approval feedback meeting. Such meetings are used to discuss the quality of the application and to evaluate the communication process during drug development and marketing application review. The purpose is to learn from successful aspects of the review process and to identify areas that could benefit from improvement. If you would like to have such a meeting with us, call the Regulatory Project Manager for this application.

If you have any questions, call Alison Rodgers, Regulatory Project Manager, at 301-796-0797.

Sincerely,

{See appended electronic signature page}

John Farley, MD, MPH
Director
Office of Infectious Diseases
Office of New Drugs
Center for Drug Evaluation and Research

ENCLOSURE(S):

- Content of Labeling
 - o Prescribing Information
- Carton and Container Labeling

This is a representation of an electronic record that was signed electronically. Following this are manifestations of any and all electronic signatures for this electronic record.

/s/

JOHN J FARLEY
07/16/2021 01:33:09 PM